文献速递临床试验与 GCP流行病学与生物统计

布基纳法索大规模阿奇霉素分发预防儿童死亡:CHAT随机临床试验

Mass Azithromycin Distribution to Prevent Child Mortality in Burkina Faso: The CHAT Randomized Clinical Trial.
PubMed 文献 · JAMA · 2024-01-01

该集群随机安慰剂对照试验在布基纳法索西北部农村Nouna地区341个社区开展,纳入1至59月龄儿童,评估在同时实施季节性疟疾化学预防的情况下,每年两次单剂口服阿奇霉素分发能否降低全因儿童死亡率。阿奇霉素组死亡498例(8.2例/1000人年),安慰剂组588例(10.0例/1000人年),发病率比0.82(95%CI 0.67-1.02;P=0.07),差异未达统计学显著;作者认为研究可能把握度不足。

要点

  • 在同时开展季节性疟疾化学预防的地区,每年两次大规模阿奇霉素分发使1至59月龄儿童全因死亡率下降但未达统计学显著(发病率比0.82;95%CI 0.67-1.02;P=0.07)。
  • 24至59月龄儿童发病率比为0.73(95%CI 0.57-0.94),1至11月龄为0.99(95%CI 0.72-1.36),12至23月龄为0.92(95%CI 0.67-1.27)。
  • 作者认为该研究可能把握度不足,未能检出有临床意义的差异。

核心结论

  • 在同时分发季节性疟疾化学预防药物的环境中,每年两次大规模阿奇霉素分发使1至59月龄儿童死亡率降低,但差异未达统计学显著。
  • 作者认为该研究可能把握度不足,未能检出有临床意义的差异。

研究设计与样本

  • 集群随机安慰剂对照试验,在布基纳法索西北部农村Nouna地区341个社区开展,社区按1:1比例随机接受口服阿奇霉素或安慰剂分发。
  • 参与者为研究社区内1至59月龄儿童,从2019年8月至2023年2月每年两次提供单剂治疗,共3年6次分发。
  • 主要结局为全因儿童死亡率,通过每年两次的计数普查测量。

主要发现

  • 阿奇霉素组纳入34399名儿童(平均[SD]年龄25.2[18]月),安慰剂组纳入33847名儿童(平均[SD]年龄25.6[18]月)。
  • 阿奇霉素组普查儿童中平均(SD)90.1%(16.0%)接受了计划研究药物,安慰剂组为89.8%(17.1%)。
  • 阿奇霉素组在60592人年中记录498例死亡(8.2例/1000人年),安慰剂组在58547人年中记录588例死亡(10.0例/1000人年)。
  • 与安慰剂组相比,阿奇霉素组死亡率的发病率比为0.82(95%CI 0.67-1.02;P=0.07)。
  • 1至11月龄儿童发病率比为0.99(95%CI 0.72-1.36),12至23月龄为0.92(95%CI 0.67-1.27),24至59月龄为0.73(95%CI 0.57-0.94)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者认为该研究可能把握度不足,未能检出有临床意义的差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Repeated mass distribution of azithromycin has been shown to reduce childhood mortality by 14% in sub-Saharan Africa. However, the estimated effect varied by location, suggesting that the intervention may not be effective in different geographical areas, time periods, or conditions. OBJECTIVE: To evaluate the efficacy of twice-yearly azithromycin to reduce mortality in children in the presence of seasonal malaria chemoprevention. DESIGN, SETTING, AND PARTICIPANTS: This cluster randomized placebo-controlled trial evaluating the efficacy of single-dose azithromycin for prevention of all-cause childhood mortality included 341 communities in the Nouna district in rural northwestern Burkina Faso. Participants were children aged 1 to 59 months living in the study communities. INTERVENTIONS: Communities were randomized in a 1:1 ratio to receive oral azithromycin or placebo distribution. Children aged 1 to 59 months were offered single-dose treatment twice yearly for 3 years (6 distributions) from August 2019 to February 2023. MAIN OUTCOMES AND MEASURES: The primary outcome was all-cause childhood mortality, measured during a twice-yearly enumerative census. RESULTS: A total of 34 399 children (mean [SD] age, 25.2 [18] months) in the azithromycin group and 33 847 children (mean [SD] age, 25.6 [18] months) in the placebo group were included. A mean (SD) of 90.1% (16.0%) of the censused children received the scheduled study drug in the azithromycin group and 89.8% (17.1%) received the scheduled study drug in the placebo group. In the azithromycin group, 498 deaths were recorded over 60 592 person-years (8.2 deaths/1000 person-years). In the placebo group, 588 deaths were recorded over 58 547 person-years (10.0 deaths/1000 person-years). The incidence rate ratio for mortality was 0.82 (95% CI, 0.67-1.02; P = .07) in the azithromycin group compared with the placebo group. The incidence rate ratio was 0.99 (95% CI, 0.72-1.36) in those aged 1 to 11 months, 0.92 (95% CI, 0.67-1.27) in those aged 12 to 23 months, and 0.73 (95% CI, 0.57-0.94) in those aged 24 to 59 months. CONCLUSIONS AND RELEVANCE: Mortality in children (aged 1-59 months) was lower with biannual mass azithromycin distribution in a setting in which seasonal malaria chemoprevention was also being distributed, but the difference was not statistically significant. The study may have been underpowered to detect a clinically relevant difference. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03676764.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Oldenburg CE, Ouattara M, Bountogo M, et al. Mass Azithromycin Distribution to Prevent Child Mortality in Burkina Faso: The CHAT Randomized Clinical Trial. JAMA. 2024. PMID: 38349371. doi:10.1001/jama.2023.27393

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。